ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
暂无分享,去创建一个
Michael A. Davies | C. Lovly | Huiqin Chen | Wanleng Deng | Huiqin Chen | W. Deng | Christine M. Lovly | Merrida A. Childress | Stephen M. Himmelberg | M. Davies
[1] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[2] A. Iafrate,et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Shaw,et al. Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] P. Stephens,et al. Identification of NTRK fusions in pediatric mesenchymal tumors , 2017, Pediatric blood & cancer.
[5] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[6] K. Park,et al. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.
[8] M. Ladanyi,et al. A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers , 2016, The Lancet. Oncology.
[9] Y. Yatabe,et al. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Gary K. Schwartz,et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer , 2015, Nature.
[11] K. Politi,et al. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer , 2015, Clinical Cancer Research.
[12] Shibing Deng,et al. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. , 2015, Cancer cell.
[13] R. Bayliss,et al. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. , 2015, The Biochemical journal.
[14] C. Tognon,et al. Detecting and targetting oncogenic fusion proteins in the genomic era , 2015, Biology of the cell.
[15] S. Stagg,et al. TFG clusters COPII‐coated transport carriers and promotes early secretory pathway organization , 2015, The EMBO journal.
[16] D. Takai,et al. Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3. , 2015, Biochemical and biophysical research communications.
[17] Y. Ko,et al. Identification of RANBP2–ALK fusion in ALK positive diffuse large B‐cell lymphoma , 2014, Hematological oncology.
[18] Samuel E. Donovan,et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. , 2014, The Journal of clinical endocrinology and metabolism.
[19] D. Ito,et al. Evidence of TRK-Fused Gene (TFG1) function in the ubiquitin–proteasome system , 2014, Neurobiology of Disease.
[20] P. Stephens,et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.
[21] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[22] D. Fennell,et al. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain , 2014, Proceedings of the National Academy of Sciences.
[23] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[24] R. Palmer,et al. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.
[25] W. Pao,et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.
[26] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[27] A. Hoelz,et al. Structural and functional analysis of the C-terminal domain of Nup358/RanBP2. , 2013, Journal of molecular biology.
[28] A. Shaw,et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. , 2013, Cancer discovery.
[29] A. Audhya,et al. Inhibition of TFG function causes hereditary axon degeneration by impairing endoplasmic reticulum structure , 2013, Proceedings of the National Academy of Sciences.
[30] R. Roskoski,et al. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. , 2013, Pharmacological research.
[31] Roman K. Thomas,et al. Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants , 2012, Clinical Cancer Research.
[32] S. Beausoleil,et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. , 2012, Cancer research.
[33] A. Warth,et al. A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] O. Delattre,et al. Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment , 2012, PloS one.
[35] H. Sakamoto,et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). , 2012, Bioorganic & medicinal chemistry.
[36] Tatiana G. Kutateladze,et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[37] S. Constantinescu,et al. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK , 2011, Haematologica.
[38] Roman K. Thomas,et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. , 2011, Cancer research.
[39] P. Ram,et al. Abstract 4920: Integrative identification of stochastically activated signaling sub-networks in individual cancer cells , 2011 .
[40] Wei-Lien Wang,et al. Epithelioid Inflammatory Myofibroblastic Sarcoma: An Aggressive Intra-abdominal Variant of Inflammatory Myofibroblastic Tumor With Nuclear Membrane or Perinuclear ALK , 2011, The American journal of surgical pathology.
[41] Glen Spraggon,et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. , 2010, The Biochemical journal.
[42] E. Remmers,et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1‐alpha of protein kinase A (PRKAR1A): an update , 2010, Human mutation.
[43] C. Hoogenraad,et al. Bicaudal D2, Dynein, and Kinesin-1 Associate with Nuclear Pore Complexes and Regulate Centrosome and Nuclear Positioning during Mitotic Entry , 2010, PLoS biology.
[44] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[45] Jen-Chieh Lee,et al. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. , 2008, Human pathology.
[46] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[47] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[48] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[49] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[50] F. Herberg,et al. Novel, isotype-specific sensors for protein kinase A subunit interaction based on bioluminescence resonance energy transfer (BRET). , 2006, Cellular signalling.
[51] E. Campo,et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells , 2004, Oncogene.
[52] P. Sorensen,et al. Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity , 2004, Molecular and Cellular Biology.
[53] J. Cowell,et al. The Oncogenic Fusion Protein-tyrosine Kinase ZNF198/Fibroblast Growth Factor Receptor-1 Has Signaling Function Comparable with Interleukin-6 Cytokine Receptors* , 2003, The Journal of Biological Chemistry.
[54] Kenneth M. Yamada,et al. Fibronectin at a glance , 2002, Journal of Cell Science.
[55] Beatriz Bellosillo,et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. , 2002, The American journal of pathology.
[56] K. Suprenant,et al. The Human EMAP-like Protein-70 (ELP70) Is a Microtubule Destabilizer That Localizes to the Mitotic Apparatus* , 2002, The Journal of Biological Chemistry.
[57] A. Rosenwald,et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. , 1999, Blood.
[58] Jonathan D. Licht,et al. Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .
[59] A. Lupas,et al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain , 1995, Molecular and cellular biology.
[60] P. S. Kim,et al. Structure of the Bcr-Abl oncoprotein oligomerization domain , 2002, Nature Structural Biology.
[61] J. Licht,et al. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.
[62] Susan S. Taylor,et al. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. , 1990, Annual review of biochemistry.